HealthcareServices

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Forecast 2025–2034: Where Businesses Should Invest Next

November 26, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market From 2025 To 2034?

The poly adp-ribose polymerase (parp) inhibitor market size has shown rapid expansion in recent years. This market is expected to increase from $8.39 billion in 2024 to $9.28 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.6%. Historically, the growth witnessed can be ascribed to clinical research, regulatory approvals, market competition, drug combinations, and patient advocacy.

The poly adp-ribose polymerase (parp) inhibitor market size is expected to experience substantial growth in the upcoming years. It is projected to expand to $13.81 billion by 2029, achieving a compound annual growth rate (CAGR) of 10.4%. This growth during the forecast period can be attributed to factors such as expanded treatment indications, advances in personalized medicine, the development of biomarkers, health economics considerations, and the rise of emerging markets. Significant trends for this period include precision medicine, ongoing advancements in immunotherapy, the evolution of targeted therapies, the application of artificial intelligence in drug discovery, and a focus on patient-centric healthcare.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp

What Are The Main Drivers Boosting The Poly ADP-Ribose Polymerase (PARP) Inhibitor Industry’s Expansion?

The escalating incidence of ovarian cancer is anticipated to fuel the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market moving ahead. Ovarian cancer is characterized as a malignant tumor forming in one or both ovaries, essential components of the female reproductive system responsible for egg and hormone production. The rise in ovarian cancer cases is influenced by factors such as genetic predisposition, an aging demographic, environmental exposures, and hormonal imbalances. Poly ADP-Ribose Polymerase (PARP) Inhibitors serve in ovarian cancer therapy by targeting DNA repair pathways, especially in individuals with BRCA mutations, resulting in synthetic lethality and increased death of tumor cells. A notable example is the projection by the World Ovarian Cancer Coalition, a Canada-based non-profit organization, that in February 2024, annual deaths from ovarian cancer among women are expected to reach 350,956, representing an increase of nearly 70% from 2022. Consequently, the growing occurrence of ovarian cancer is propelling the development of the poly ADP-ribose polymerase (PARP) inhibitor market.

What Are The Leading Segments Analyzed In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

The poly adp-ribose polymerase (parp) inhibitormarket covered in this report is segmented –

1) By Drug Type: Talazoparib; Veliparib; Olaparib; Other Drug Types

2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels

3) By Application: Ovarian Cancer; Breast Cancer; Other Applications

4) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users

Subsegments:

1) By Talazoparib: Talazoparib For Breast Cancer; Talazoparib For Ovarian Cancer; Talazoparib For Prostate Cancer; Talazoparib For Other Cancers

2) By Veliparib: Veliparib For Breast Cancer; Veliparib For Ovarian Cancer; Veliparib For Non-Small Cell Lung Cancer (Nsclc); Veliparib For Other Cancers

3) By Olaparib: Olaparib For Breast Cancer (Her2-negative); Olaparib For Ovarian Cancer (Brca-mutated); Olaparib For Prostate Cancer (Brca-Mutated); Olaparib For Pancreatic Cancer (Brca-Mutated); Olaparib For Other Cancers

4) By Other Drug Types: Niraparib; Rucaparib; Pembrolizumab (Combination Therapy With Parp Inhibitors); Other Parp Inhibitors (Emerging Drugs In Clinical Trials)

What Trends Are Expected To Drive The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

Key companies within the poly ADP-ribose polymerase (PARP) inhibitor market are developing generic PARP inhibitors to provide a customized treatment strategy for cancer patients with specific genetic mutations. These generic PARP inhibitors are drugs designed to block the activity of the enzyme poly ADP-ribose polymerase (PARP). As an illustration, in March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, introduced Olaparib, a PARP inhibitor under the IBYRA brand, with the goal of increasing access to advanced cancer treatment. IBYRA is directed at specific genetic mutations identified in breast, ovarian, prostate, and pancreatic cancers, thus offering a personalized and effective therapeutic approach. The drug is particularly advantageous for patients presenting with HRD-positive or BRACA mutations, helping to slow down the progression of the disease.

Which Global Market Leaders Are Shaping The Future Of The Poly ADP-Ribose Polymerase (PARP) Inhibitor Sector?

Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/poly-adp-ribose-polymerase-parp-inhibitor-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15637&type=smp

Browse Through More Reports Similar to the Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market 2025, By The Business Research Company

Her2 Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report

Checkpoint Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Protein Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795